Remibrutinib results in significant improvement in patients still symptomatic after second-generation H1-antihistamine treatment.

Dr Adam Friedman recounts how AAD 2025 highlighted advancements in chronic spontaneous urticaria management, with discussion ...

Remibrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria in two identical randomized ...

Skin reactions can be alarming, especially when they appear suddenly. Many people struggle to tell the difference between ...

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch ...

For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H 1-antihistamines, administration of the oral, highly selective Bruton's tyrosine kinase ...

Morgan Stanley backs Celldex Therapeutics for growth with barzolvolimab's market-leading potential in chronic urticaria. Read ...

Xyzal (levocetirizine) and Zyrtec (cetirizine) are over-the-counter (OTC) allergy medications. Learn about their key ...

0.3% in the combined groups). Treatment with oral remibrutinib resulted in a significant improvement in a composite measure of itching and hives at week 12. (Funded by Novartis Pharmaceuticals ...

In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on ...